Indications and uses
Helps prevent sunburn. Higher SPF gives more sunburn protection. Provides moderate protection against sunburn.
ESIKA
- Manufacturer
- Ventura Corporation (San Juan, P.R) | Bel Star S.A. (Colombia)
- Effective date
- 2011-05-17
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:51:27
Label at a glance#
ProductESIKA Hydro-Nutrative Foundation SPF 13
Active ingredientOctinoxate, Oxybenzone
Label structure20 sections
Dosage and administration
Apply smootly every morning before sun exposure and as needed. Apply to the forehead, nose, chin and both cheeks. Blend with circular motion and spread softly. Moderate sun protection product.
Storage and handling
Sun alert: Limiting sun exposure, wearing protective clothing, and using sunscreens may reduce the risk of skin aging, skin cancer, and other harmful effects of the sun.
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
Active Ingredients
Octinoxate (5%), Oxybenzone (2%)
Purpose
Sunscreen
Uses
- Helps prevent sunburn.
- Higher SPF gives more sunburn protection.
- Provides moderate protection against sunburn.
Warnings
- For external use only
OTC - WHEN USING SECTION
- When using this product keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
- Stop use and ask a doctor if rash and irritation develops and lasts.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
- Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- Apply smootly every morning before sun exposure and as needed.
- Apply to the forehead, nose, chin and both cheeks. Blend with circular motion and spread softly.
- Moderate sun protection product.
Other information
- Sun alert: Limiting sun exposure, wearing protective clothing, and using sunscreens may reduce the risk of skin aging, skin cancer, and other harmful effects of the sun.
Inactive ingredients
Aqua (water), cyclomethicone, cyclopentasiloxane, talc, cetyl peg/ppg-10/1 dimethicone, polyglyceryl-4 isostearate, pisum sativum (pea) extract), peg-12 dimethicone crosspolymer, hexyl laurate, isostearyl neopentanoate, disteardimonium hectorite, cyclohexasiloxane, rosa centifolia flower water, sodium chloride, mannitol, dimethicone, propylene carbonate, propylene glycol, phenoxyethanol, octyldodecanol, butylene glycol, dimethiconol, methylparaben, propylparaben, cetearyl dimethicone crosspolymer, tocopheryl acetate, microcristallina cera (microcrystalline wax), methicone, polymethylsilsesquioxane, petrolatum, phospholipids, bha, bht, cyclodextrin, butylparaben, ethylparaben, cholesterol, faex extract (yeast extract), isobutylparaben, candelilla cera (euphorbia cerifera (candelilla) wax), cera alba (beeswax), cetearyl alcohol, cetearyl glucoside, copernicia cerifera cera (copernicia cerifera (carnauba) wax), polyglyceryl-2 dipolyhydroxystearate, olea europaea oil unsaponifiables (olea europaea (olive) oil unsaponifiables), glycosphingolipids, disodium succinate. May contain: CI 77891 (titanium dioxide), CI 77492 (iron oxides), CI 77491 (iron oxides), CI 77499 (iron oxides).
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Beige 1
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Beige 2
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Beige 3
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Beige 4
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Beige 5
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Beige 6
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Rosa 1
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Rosa 2
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Rosa 3
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Rosa 4
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Rosa 5
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
PRINCIPAL DISPLAY PANEL - 30 ml Carton - Rosa 6
ēsika
Hydro-Nutritive
Foundation
SPF 13
30 ml e (1 fl.oz.)
FDA-Initiated Inactive NDC Indexing#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| Oxybenzone | ACTIVE INGREDIENT | 95OOS7VE0Y | 1 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| Oxybenzone | ACTIVE MOIETY | 95OOS7VE0Y | 1 | |
| butylated hydroxyanisole | INACTIVE INGREDIENT | REK4960K2U | 1 | |
| butylated hydroxytoluene | INACTIVE INGREDIENT | 1P9D0Z171K | 1 | |
| butylene glycol | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| butylparaben | INACTIVE INGREDIENT | 3QPI1U3FV8 | 1 | |
| candelilla wax | INACTIVE INGREDIENT | WL0328HX19 | 1 | |
| carnauba wax | INACTIVE INGREDIENT | R12CBM0EIZ | 1 | |
| cetearyl glucoside | INACTIVE INGREDIENT | 09FUA47KNA | 1 | |
| cetostearyl alcohol | INACTIVE INGREDIENT | 2DMT128M1S | 1 | |
| cholesterol | INACTIVE INGREDIENT | 97C5T2UQ7J | 1 | |
| cyclomethicone | INACTIVE INGREDIENT | NMQ347994Z | 1 | |
| cyclomethicone 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 1 | |
| cyclomethicone 6 | INACTIVE INGREDIENT | XHK3U310BA | 1 | |
| dimethicone | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| ethylparaben | INACTIVE INGREDIENT | 14255EXE39 | 1 | |
| ferric oxide red | INACTIVE INGREDIENT | 1K09F3G675 | 1 | |
| ferric oxide yellow | INACTIVE INGREDIENT | EX438O2MRT | 1 | |
| ferrosoferric oxide | INACTIVE INGREDIENT | XM0M87F357 | 1 | |
| hexyl laurate | INACTIVE INGREDIENT | 4CG9F9W01Q | 1 | |
| isobutylparaben | INACTIVE INGREDIENT | 0QQJ25X58G | 1 | |
| mannitol | INACTIVE INGREDIENT | 3OWL53L36A | 1 | |
| methylparaben | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| microcrystalline wax | INACTIVE INGREDIENT | XOF597Q3KY | 1 | |
| octyldodecanol | INACTIVE INGREDIENT | 461N1O614Y | 1 | |
| olive oil | INACTIVE INGREDIENT | 6UYK2W1W1E | 1 | |
| pea | INACTIVE INGREDIENT | W4X7H8GYFM | 1 | |
| petrolatum | INACTIVE INGREDIENT | 4T6H12BN9U | 1 | |
| phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| polyglyceryl-4 isostearate | INACTIVE INGREDIENT | 820DPX33S7 | 1 | |
| propylene carbonate | INACTIVE INGREDIENT | 8D08K3S51E | 1 | |
| propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| propylparaben | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| rosa centifolia flower oil | INACTIVE INGREDIENT | H32V31VMWY | 1 | |
| sodium chloride | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| sodium succinate anhydrous | INACTIVE INGREDIENT | V8ZGC8ISR3 | 1 | |
| talc | INACTIVE INGREDIENT | 7SEV7J4R1U | 1 | |
| titanium dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| yeast | INACTIVE INGREDIENT | 3NY3SM6B8U | 1 | |
| yellow wax | INACTIVE INGREDIENT | 2ZA36H0S2V | 1 |
Products#
Every source-derived product name is available through these pages.
- ESIKA Hydro-Nutrative Foundation SPF 13
- Octinoxate and Oxybenzone
- Octinoxate
- Oxybenzone
- water
- cyclomethicone
- cyclomethicone 5
- talc
- polyglyceryl-4 isostearate
- pea
- hexyl laurate
- cyclomethicone 6
- rosa centifolia flower oil
- sodium chloride
- mannitol
- dimethicone
- propylene carbonate
- propylene glycol
- phenoxyethanol
- octyldodecanol
- butylene glycol
- methylparaben
- propylparaben
- microcrystalline wax
- petrolatum
- butylated hydroxyanisole
- butylated hydroxytoluene
- butylparaben
- ethylparaben
- cholesterol
- yeast
- isobutylparaben
- candelilla wax
- yellow wax
- cetostearyl alcohol
- cetearyl glucoside
- carnauba wax
- olive oil
- sodium succinate anhydrous
- titanium dioxide
NDC Codes#
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / VAGINAL | 750 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INFILTRATION | 3535 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | CAPSULE, COATED PELLETS / ORAL | 14 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / AURICULAR (OTIC) | 18 mg | ||
| butylated hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SPRAY, METERED / NASAL | 0.1 mg/1ml | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE, EXTENDED RELEASE / ORAL | 41 mg | ||
| ferrosoferric oxide | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE, DELAYED RELEASE / ORAL | 6 mg | ||
| carnauba wax | CARNAUBA WAX | R12CBM0EIZ | GUM, CHEWING / BUCCAL | 10 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | GUM, CHEWING / BUCCAL | 182 mg | ||
| talc | TALC | 7SEV7J4R1U | CAPSULE, COATED / ORAL | 87 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION / PERINEURAL | 80 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | POWDER, FOR SUSPENSION / INTRAMUSCULAR | 6.75 %w/v | ||
| ferric oxide red | FERRIC OXIDE RED | 1K09F3G675 | TABLET, DELAYED RELEASE / ORAL | 37 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET / ORAL | 3391 mg | ||
| butylparaben | BUTYLPARABEN | 3QPI1U3FV8 | SUSPENSION / ORAL | 12 mg | ||
| cetostearyl alcohol | CETOSTEARYL ALCOHOL | 2DMT128M1S | OINTMENT / TOPICAL | 1.2 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRATUMOR | 1.2 %w/v | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / AURICULAR (OTIC) | NA | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / RECTAL | 3315 mg | ||
| butylated hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | SUSPENSION / ORAL | 2.5 mg/5ml | ||
| carnauba wax | CARNAUBA WAX | R12CBM0EIZ | TABLET / ORAL | 167.8 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / ORAL | 29008 mg | ||
| butylated hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CAPSULE, EXTENDED RELEASE / ORAL | 0.03 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / TOPICAL | 0.8 %w/w | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SYRUP / ORAL | 81 mg | ||
| ferric oxide red | FERRIC OXIDE RED | 1K09F3G675 | TABLET / SUBLINGUAL | 1 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RESPIRATORY (INHALATION) | 0.03 %w/w | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | FILM / BUCCAL | 1 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / OPHTHALMIC | 0.44 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBCUTANEOUS | 1486 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / DENTAL | NA | ||
| butylated hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | GEL / TOPICAL | 7 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / ORAL | 346 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION / INTRAMUSCULAR | 106.6 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, EXTENDED RELEASE / ORAL | 67 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / SUBCUTANEOUS | 2 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACAVITARY | 0.82 %w/v | ||
| butylated hydroxytoluene | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | NA | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SOLUTION / INTRAMUSCULAR | 5 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAVASCULAR | NA | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SWAB / TOPICAL | 34.6 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAOCULAR | 320 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, METERED / RECTAL | NA | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION / INFILTRATION | 80 mg | ||
| yellow wax | YELLOW WAX | 2ZA36H0S2V | TABLET, SUGAR COATED / ORAL | NA | ||
| phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | CREAM / TOPICAL | 57 mg | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 181 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SUSPENSION / INTRAMUSCULAR | 0.02 %w/v | ||
| mannitol | MANNITOL | 3OWL53L36A | SOLUTION/ DROPS / OPHTHALMIC | 4.6 %w/v | ||
| butylated hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | OINTMENT / VAGINAL | 0.02 %w/w | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRALESIONAL | 0.02 %w/v | ||
| talc | TALC | 7SEV7J4R1U | TABLET, SUGAR COATED / ORAL | NA | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION/ DROPS / OPHTHALMIC | 0.01 %w/w | ||
| titanium dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE / ORAL | 55 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 658 mg | ||
| butylparaben | BUTYLPARABEN | 3QPI1U3FV8 | TABLET, COATED / ORAL | 0.08 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 33790c8c-da30-619f-e063-6294a90a7c48 | 1aabcfbc-0d5e-4e13-ac23-a06f5910f152 | 2025-04-23 | Warnings | 1aabcfbc-0d5e-4e13-ac23-a06f5910f152 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.